EASD
<ѻý class="page-description">European Association for the Study of Diabetesѻý>Three-day intervention boosted time spent in normal glucose range
But significant weight loss reported for both
Relationship was mediated by comorbid dyslipidemia
Saxenda group six times more likely to lose at least 5% of BMI
But higher severe hypoglycemia risk with efsitora in type 1 diabetes likely precludes its use
Those with the most metabolic changes, genetic risk had a threefold higher diabetes risk
The faster formulation led to fewer hypoglycemia events versus conventional insulin aspart
However, no FDA-approved systems have a pregnancy indication yet
EMERGE trial misses on primary endpoint, but secondary outcomes suggest potential benefit
Results with the GIP/GLP-1 receptor agonist were statistically superior to added insulin lispro
Data support looking at enterovirus vaccination for prevention
Systematic review indicates vast sex differences in youth with type 1 diabetes
Other groups at risk for early mortality include smokers, those diagnosed at younger ages
Preservation of ovaries played into this association
-
Obesity Week: The Obesity Society
November 2024
-
EASD: European Association for the Study of Diabetes
September 2024
-
ENDO: The Endocrine Society
June 2024
-
AACE: American Association of Clinical Endocrinology
May 2024